Literature DB >> 20635906

Chimeric T cells for adoptive immunotherapy of cancer: using what have we learned to plan for the future.

Stefan Peinert, Michael H Kershaw, H Miles Prince.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 20635906     DOI： 10.2217/imt.09.69

Source DB:  PubMed          Journal:  Immunotherapy        ISSN： 1750-743X            Impact factor:   4.196


× No keyword cloud information.
  5 in total

Review 1.  Is cancer gene therapy an empty suit?

Authors:  Malcolm K Brenner; Stephen Gottschalk; Ann M Leen; Juan F Vera
Journal:  Lancet Oncol       Date:  2013-10       Impact factor: 41.316

2.  Elimination of progressive mammary cancer by repeated administrations of chimeric antigen receptor-modified T cells.

Authors:  Anat Globerson-Levin; Tova Waks; Zelig Eshhar
Journal:  Mol Ther       Date:  2014-02-27       Impact factor: 11.454

Review 3.  Engineered T cells for cancer treatment.

Authors:  Usanarat Anurathapan; Ann M Leen; Malcolm K Brenner; Juan F Vera
Journal:  Cytotherapy       Date:  2013-11-13       Impact factor: 5.414

Review 4.  Current translational and clinical practices in hematopoietic cell and gene therapy.

Authors:  David L Digiusto; Hans-Peter Kiem
Journal:  Cytotherapy       Date:  2012-08       Impact factor: 5.414

5.  Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling.

Authors:  Scott Wilkie; May C I van Schalkwyk; Steve Hobbs; David M Davies; Sjoukje J C van der Stegen; Ana C Parente Pereira; Sophie E Burbridge; Carol Box; Suzanne A Eccles; John Maher
Journal:  J Clin Immunol       Date:  2012-04-17       Impact factor: 8.317
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.